Hyperuricemia Pipeline Shows Promise with 15+ Emerging Therapies in Development
• Global hyperuricemia pipeline comprises 12+ key companies developing 15+ treatment therapies across various clinical stages, according to DelveInsight's 2025 report.
• Leading companies in hyperuricemia drug development include LG Chem, Shanton Pharma, InventisBio, Jiangsu HengRui Medicine, and Selecta Biosciences, with treatments spanning oral, intravenous, and subcutaneous administration routes.
• A significant development occurred in December 2024 when Atom Therapeutics partnered with China Medical System Holdings to commercialize lingdolinurad (ABP-671), a novel URAT1 inhibitor for chronic gout and hyperuricemia in China.
© Copyright 2025. All Rights Reserved by MedPath